000 01315 a2200385 4500
005 20250515044917.0
264 0 _c20071015
008 200710s 0 0 ger d
022 _a0028-2804
024 7 _a10.1007/s00115-006-2194-8
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aFleischhacker, W W
245 0 0 _a[Pharmacotherapy for schizophrenia].
_h[electronic resource]
260 _bDer Nervenarzt
_cNov 2006
300 _aS77-97; S98 p.
_bdigital
500 _aPublication Type: English Abstract; Journal Article; Review
650 0 4 _aAcute Disease
650 0 4 _aAntipsychotic Agents
_xadverse effects
650 0 4 _aBasal Ganglia Diseases
_xchemically induced
650 0 4 _aDrug Resistance
650 0 4 _aEvidence-Based Medicine
650 0 4 _aHumans
650 0 4 _aLong-Term Care
650 0 4 _aPractice Guidelines as Topic
650 0 4 _aQuality of Life
_xpsychology
650 0 4 _aSchizophrenia
_xdiagnosis
650 0 4 _aSchizophrenic Psychology
650 0 4 _aSecondary Prevention
650 0 4 _aSocial Adjustment
650 0 4 _aTreatment Outcome
650 0 4 _aViolence
_xprevention & control
700 1 _aHummer, W
773 0 _tDer Nervenarzt
_gvol. 77 Suppl 2
_gp. S77-97; S98
856 4 0 _uhttps://doi.org/10.1007/s00115-006-2194-8
_zAvailable from publisher's website
999 _c16656446
_d16656446